Treatment of Initial Herpes Outbreak
For a first episode of genital herpes, treat with oral acyclovir 200 mg five times daily for 7-10 days, or alternatively valacyclovir 1000 mg twice daily for 10 days, continuing until clinical resolution is achieved.
Primary Treatment Regimen
The CDC guidelines consistently recommend oral antiviral therapy for first clinical episodes of genital herpes 1. The standard approach is:
- Acyclovir 200 mg orally 5 times daily for 7-10 days (or until clinical resolution)
- Alternative: Valacyclovir 1000 mg twice daily for 10 days 2, 3
The 1998 CDC guidelines 4 expanded options but maintained acyclovir as the foundational treatment. Valacyclovir has been shown to be equally effective as acyclovir with the significant advantage of twice-daily dosing versus five-times-daily, which improves compliance 3.
Key Clinical Considerations
Duration of Treatment
Continue treatment for 7-10 days or until clinical resolution, whichever is longer 1. The longer duration (10 days) is particularly important for:
- Primary infections (no preexisting HSV antibodies)
- More severe presentations
- Patients with extensive lesions
Special Presentations
Herpes Proctitis: Requires higher dosing
- Acyclovir 400 mg orally 5 times daily for 10 days 1
Severe Disease Requiring Hospitalization: Switch to intravenous therapy
- Acyclovir 5-10 mg/kg IV every 8 hours for 5-7 days 1
- Indications include disseminated infection, encephalitis, pneumonitis, or hepatitis
Immunocompromised Patients
HIV-infected and other immunocompromised patients may require more aggressive and prolonged therapy 1. These patients are at higher risk for:
- Acyclovir-resistant strains
- Prolonged episodes with extensive disease
- Treatment failures with standard regimens
Close monitoring is essential, and alternative agents (foscarnet, cidofovir) may be needed for resistant cases 5.
Critical Pitfalls to Avoid
Do NOT use topical acyclovir - it is substantially less effective than oral therapy and its use is discouraged 1. Systemic oral therapy is required for adequate treatment.
Do NOT assume treatment prevents latency - Acyclovir and valacyclovir provide partial control of symptoms but neither eradicate latent virus nor affect the subsequent risk, frequency, or severity of recurrences after discontinuation 1.
Patient Counseling Requirements
Essential counseling at initial presentation includes 4, 1:
- Natural history with emphasis on potential for recurrent episodes
- Asymptomatic viral shedding occurs and enables transmission
- Abstain from sexual activity when lesions or prodromal symptoms present
- Condom use during all sexual exposures with new/uninfected partners
- Risk of neonatal infection (inform all patients, including men)
- Women of childbearing age must inform prenatal care providers
Evidence Quality
The recommendations are based on CDC STD Treatment Guidelines 1, 4, which represent the highest quality guideline evidence available. Randomized controlled trials demonstrate that systemic acyclovir provides partial control of symptoms and signs during first clinical episodes 1, 6. Valacyclovir has been validated as equally effective with superior bioavailability and more convenient dosing 3.
The 2022 CDC guidelines 7 continue to support these treatment approaches while acknowledging ongoing research into novel agents like helicase-primase inhibitors, though these remain investigational.